Townsville Hospital

Running trials

• Recruiting

  A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  NCT06980480· Phase 3· Takeda· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Active, not recruiting

  A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

  NCT06456463· Phase 2· Stemline Therapeutics, Inc.· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

  NCT05883956· Phase 3· Otsuka Australia Pharmaceutical Pty Ltd· Source

• Active, not recruiting

  A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT04819100· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

  NCT04958239· Phase 1· Boehringer Ingelheim· Source

• Active, not recruiting

  Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

  NCT04291885· Phase 2· Melanoma and Skin Cancer Trials Limited· Source

• Active, not recruiting

  Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

  NCT04136353· Phase 3· University of Sydney· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· University of Leicester· Source

• Recruiting

  The EXCEL Registry of Patients Requiring ECMO

  NCT03793257· Australian and New Zealand Intensive Care Research Centre· Source

• Active, not recruiting

  Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

  NCT02170090· Phase 3· Universitätsklinikum Hamburg-Eppendorf· Source

• Active, not recruiting

  Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

  NCT02446405· Phase 3· University of Sydney· Source

• Active, not recruiting

  Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

  NCT02446444· Phase 3· University of Sydney· Source

• Active, not recruiting

  Improving the Treatment for Women With Early Stage Cancer of the Uterus

  NCT01686126· Phase 2· Queensland Centre for Gynaecological Cancer· Source

• Active, not recruiting

  Radiotherapy - Adjuvant Versus Early Salvage

  NCT00860652· Trans Tasman Radiation Oncology Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Aortic stenosis1 recruiting
• IgA nephropathy1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Comprehensive Geriatric Assessment for Frail Older People With Chronic Kidney Disease - The GOAL Trial

  NCT04538157· The University of Queensland· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Terminated

  Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

  NCT03616470· Phase 3· GlycoMimetics Incorporated· Source

• Completed

  Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

  NCT02486718· Phase 3· Hoffmann-La Roche· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Aortic aneurysm11 works · 0 trials
• Peripheral artery disease10 works · 0 trials
• Polycystic kidney disease3 works · 0 trials